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ABSTRACT
Introduction: Dapagliflozin, a sodium glucose
co-transporter 2 (SGLT2) inhibitor, is a
promising drug approved for the treatment of
type 2 diabetes mellitus (T2DM). However, its
cost is an obstacle for use in developing
countries like India. Thus, we aimed to analyse
the impact on the cost of insulin therapy after
adding dapagliflozin for patients using insulin
in real-world clinical practice.
Methods: This retrospective chart review study
included patients with uncontrolled T2DM
previously on maximum doses of OADs and
insulin therapy, initiated on dapagliflozin.
Parameters measured were: HbA1c, changes in
weight and insulin dosage, frequency and cost,
at baseline and after 3 months of adding
dapagliflozin 10 mg. Hospital records of
patients attending the diabetes outpatient
departments at the study centres were
scrutinised to identify eligible patients. A
treat-to-target approach was used to make
changes in the insulin dosages and regimen.
The cost of insulin was calculated based on the
total daily dose, cost per unit based on the
formulation and insulin delivery device.
Statistical analysis included descriptive and
inferential methods.
Results: Overall, 70 patients meeting the
inclusion criteria were included in the study.
The mean age of patients and duration of T2DM
were 52.6 ± 10 and 12 ± 5 years respectively.
The mean reduction in HbA1c and weight was
2.1 ± 1% (p\0.01) and 2.4 ± 1 kg (p\0.01)
respectively. Genital mycotic infections were
reported in two (2.8%) patients. The mean
reduction in the total daily dose of insulin was
9.5 ± 6 units. A significant reduction in the
daily insulin requirement (19.87%, p\0.01)
was observed. The cost of insulin decreased by
22.3% or 17.8 ± 15 INR per day ($0.27 ± 0.22
per day) and the frequency of insulin shots
administered per day decreased significantly
(p\0.01). In 12.8% and 2.8% of patients the
frequency of administration of insulin
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decreased by one and two injections per day
respectively.
Conclusions: Reduction in HbA1c and body
weight along with minimal side effects was
observed. Addition of dapagliflozin reduced the
insulin daily dose requirement and cost of
insulin therapy in these patients.
Funding: Diacon Hospital, Bangalore, India.
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INTRODUCTION
The prevalence of diabetes and especially type 2
diabetes mellitus (T2DM) is on the rise with a
prevalence of 415 million cases globally and
69.1 million cases of diabetes in India in 2015
[1]. With the increasing incidence, cost of
health care, lack of education, lack of lifestyle
modifications, side effects of medications and
physician inertia to up-titrate medications are
factors amongst many that contribute to
hyperglycaemia. In addition to its impact on
micro- and macro-vascular outcomes, morbidity
and mortality, the cost involved in the
treatment of diabetes to the health care system
is enormous [2, 3]. The individual expenditure
to have access to standard care is 2.4 times
higher for a patient with T2DM than for those
without diabetes [4–10].
Patients with T2DM need constant
up-titration of their medications because of
the progressive beta cell failure [11].
Up-titration of oral and injectable antidiabetic
drugs increases the short-term cost of
medication. This is essential to improve the
glycaemic control and to reduce the long-term
costs incurred from the treatment of
diabetes-related complications. Diabetes
patients who do not achieve glycaemic control
on monotherapy can benefit by either
intensifying the dose or combination therapy
with oral anti-diabetic drugs (OADs) and insulin
[12–16]. However, insulin therapy is associated
with weight gain and increased risk of
hypoglycaemia. [16].
Sodium glucose transporter receptor 2
(SGLT2) inhibitors (with their
insulin-independent mechanism of action)
improve glycaemic control by increasing the
renal excretion of glucose. [17, 18]. The
glycaemic and extra-glycaemic benefits such as
weight loss, reduction in blood pressure, decrease
inuric acid levels, improvement incardiovascular
(CV) outcomes and renal outcomes are known
with this class of agents [19–26].Dapagliflozin, an
SGLT2 inhibitor, can be used as monotherapy or
as an adjunctive therapy in patients inadequately
controlled with existing antidiabetic
medications, including insulin [27]. However,
the cost of dapagliflozin (43.2 INR, $0.64)
remains a major challenge in clinical practice in
developing countries like India.
Thus, the current study was conducted in a
real-world clinical practice setting to evaluate
the clinical effectiveness and impact on the cost
of insulin therapy when dapagliflozin was




This retrospective chart review planned to
include patients with uncontrolled T2DM who
were previously on maximum doses of OADs
and insulin therapy. The study planned to
evaluate the clinical effectiveness of
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dapagliflozin when added to insulin therapy in
T2DM patients. In addition, the present study
attempted to evaluate the cost of insulin
therapy when it was added to dapagliflozin in
these patients.
Inclusion and Exclusion Criteria
The patients included in the study had
uncontrolled T2DM for more than 3 months,
HbA1c [8%, and were on insulin and
maximum doses of OADs, without a clinical
contraindication to receive an SGLT2 inhibitor.
They were started on dapagliflozin 10 mg once a
day. Baseline OADs prescribed by the treating
physician remained unchanged and included
sulfonylureas (glimiperide and gliclazide),
metformin, DPP4 inhibitors, pioglitazone and
alpha glucosidase inhibitors.
Patients with type 1 diabetes mellitus,
pregnancy, recurrent urinary tract infections,
genital mycotic infections and glomerular
filtration rate (GFR) \60 ml/min/1.73 m2 were
excluded from participating in this study.
Data Collection
Patients were evaluated for effectiveness and
safety based on the following parameters:
fasting plasma glucose (FPG), postprandial
plasma glucose (PPG), glycated haemoglobin
(HbA1c), lipid profile, renal function tests and
urine analysis. The treat-to-target approach was
used to adjust insulin doses as per standard of
care. The insulin regimens included basal
insulin once a day, premixed insulin twice a
day, premixed insulin before breakfast and
neutral protamine Hagedorn (NPH)/basal
insulin at night, basal plus or basal bolus
regimen. Patients were advised to do
self-monitoring of blood glucose (SMBG) and
adjust their insulin dose accordingly at home.
The initial insulin regimen was unchanged at
the time of initiation of dapagliflozin; however,
patients who had recurring hypoglycaemia
(more than three episodes in spite of reducing
insulin dose based on the SMBG monitoring at
home) were reviewed. In this subset of patients,
the insulin regimen was changed and the
frequency of insulin administration was
reduced by the treating physician.
Data Abstraction
Patients from the study centres were evaluated
for the inclusion and exclusion criteria. Overall,
the present study planned to include those
patients who had T2DM taking a combination
of OADs and insulin, in whom dapagliflozin was
initiated for the treatment of T2DM. Hospital
records of patients attending the diabetes
outpatient departments at two study centres,
namely DiaconHospital, a university-recognised
specialised private 25-bed hospital for diabetes
care, research and post-graduate studies, and
Shivajyoti, a specialised private paediatric and
adult endocrine outpatient practice hospital,
were critically examined. The patient records
between August 2015 and December 2015 were
examined for inclusion of patients in the study.
Study Outcomes
The clinical effectiveness parameters measured
were HbA1c and weight reduction. The study
also assessed reduction in the total daily dose
and frequency of insulin administration. The
cost of insulin therapy at baseline and 3 months
after adding dapagliflozin was evaluated. The
cost of insulin included the total daily dose, cost
per unit of insulin based on the formulation
and the insulin delivery device.
Safety and tolerability were assessed by
evaluating renal function tests, urinary
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ketones and urine analysis recorded before and
3 months after the addition of dapagliflozin
10 mg. Mild hypoglycaemic episodes that
occurred during the study period were not
recorded. Patients were asked to report severe
hypoglycaemic episodes, which were defined as
an event of hypoglycaemia leading to a plasma
glucose of \50 mg/dl, resulting in loss of
consciousness or requiring intravenous
administration of dextrose or hospitalisation.
Statistical Analysis
Microsoft Excel was used for the statistical
analysis. Continuous variables are presented as
mean ± standard deviation (SD) and categorical
variables are presented in percentages (%).
Continuous outcomes were tested using paired
t test and Wilcoxon signed rank test for ordinal
outcomes. P values\0.05 and 95% confidence
intervals (CI) were considered to be statistically
significant. A linear regression model was used
to study the relationships between continuous
outcomes and explanatory variables.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
RESULTS
Patient Characteristics
Overall, 5592 T2DM patient records were
available from the outpatient department. A
total of 264 patients had been initiated on
dapagliflozin. One hundred ten patients out of
these were the patients in whom dapagliflozin
had been initiated over background insulin
therapy and OADs. Of the 110 patients, 70
were included because their complete medical
record was available; however, the remaining 40
patients were excluded from the entire analysis
as they were lost to follow-up after the first
hospital visit (Fig. 1).
The mean age and percentage of male
patients were 52.6 ± 10 years and 44.3%
respectively. Overall, an amount of less than
50 INR ($0.75) and an amount of more than 100
INR ($1.49) were being spent per day on insulin
by 21 (30%) patients, and 28 (40%) patients
were spending an amount of between 50 INR
($0.75) and 100 INR ($1.49) on insulin per day.
The majority of the patients used insulin pens
and cartridges (n = 60, 85.8%) as the insulin
delivery device and a smaller proportion used
syringes and vials (n = 10, 14.2%). The detailed
demographics and baseline clinical parameters
are presented in Table 1. The patients were
taking insulin NPH, glargine, degludec, regular
insulin, aspart and lispro in different insulin
regimens at baseline. Details of the different
insulin regimens being received by patients at
baseline are presented in Table 2.
Effectiveness of Dapagliflozin on Addition
to Insulin Therapy and Reduction
in Insulin Dose
Reduction of HbA1c Levels and Changes
in Body Weight
The mean change in HbA1c from baseline to
3 months after the addition of dapagliflozin was
2.1 ± 1% [10.3 ± 2% vs. 8.2 ± 1%, (p\0.01)]
and weight reduction was 2.4 ± 1 kg [75.3 ± 13
and 72.9 ± 12, (p\0.01)] (Table 3).
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Reduction in Insulin Dose, Cost and Frequency
Insulin cost and dose at baseline and follow-up
are shown in Table 3. A clinically and
statistically significant (p\0.01) reduction in
total daily dose of insulin (9.5 ± 6 units) was
observed from baseline to the 3-month
follow-up period. There was a significant
reduction in daily cost on insulin therapy by
17.8 ± 15 INR per day ($0.27 ± 0.22, p\0.01).
The relationship between insulin dose
reduction and cost reduction was analysed. For
reduction in insulin cost, the b value of the
dosage reduction was estimated to be 1.85 units
[1.66–2.03, (p\0.01)] and did not change when
adjusted for confounders such as age, gender
and duration of diabetes. One-unit reduction in
insulin dose translated to a cost reduction of
1.85 INR ($0.03, Fig. 2).
There was a statistically significant reduction
(p\0.01) in cost after the addition of
dapagliflozin in all groups viz. patients
spending less than 50 INR ($0.75); patients
spending between 50–100 INR ($0.75–1.49);
and patients spending more than 100 INR
($1.49). Specifically, in patients (30%) whose
daily insulin expenditure exceeded 100 INR per
day ($1.49 per day), the decrease in insulin cost
was observed to be 45 INR [$0.67, baseline:
151.8 ± 33 ($2.25 ± 0.49); 3-month follow-up:
106.8 ± 29 ($1.59 ± 0.43), p\0.01, Table 3].
There was a significant reduction in the
frequency of insulin administration after the
Fig. 1 Patient disposition
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addition of dapagliflozin (p\0.01). There was a
reduction in insulin injections by one and two
injections per day in 12.8% and 2.8% of
patients respectively (Table 3).
Safety and Tolerability
Although the frequency of mild hypoglycaemic
episodes was not recorded during the study
period, none of the patients reported severe
hypoglycaemic episodes. Patients who
experienced hypoglycaemia were advised to
reduce the dose of insulin as per the standard
of care. In addition, patients experienced only
mild hypoglycaemic episodes that did not
require intravenous dextrose or
hospitalisation. Mild hypoglycaemic episodes
were self-managed at home by the patients with
oral glucose consumption (15–20 gm), which
did not add to the treatment cost as the cost of
oral glucose was minimal. Genital mycotic
infections were observed in two (2.8%)
patients and treated successfully with topical
fluconazole-based creams with no further
recurrence. The cost of treatment was a single
time additional cost of 43 INR ($0.64) per
Table 1 Demographics and baseline clinical parameters
Parameters Uncontrolled T2DM
(N5 70)
Mean age (±SD), years 52.6 ± 10
Males (%) 44.3
Mean duration of disease
(±SD), years
12 ± 5
Mean HbA1C (±SD), % 10.3 ± 2
Mean weight (±SD), kg 75.3 ± 13
Insulin total daily dose, units 47.8 ± 30
Mean insulin cost per day,
INR ($)
79.5 ± 53 (1.19 ± 0.79)
Cost of insulin per day, (INR ($)
\50 INR per day (\$0.75
per day)
21 (30%)
50–100 INR per day
($0.75–1.49 per day)
28 (40%)




Syringes and vials 10 (14.2%)
Insulin pens and cartridges 60 (85.8%)
Table 2 Different insulin regimens patients received at
baseline
Insulin regimen n (%)
Glargine OD 22 (31.4)
Premixed insulin OD
30% aspart with 70% Degludec
2 (2.8)
Premixed insulin BID
30% soluble aspart with 70% NPH
11 (15.7)
Premixed insulin BID
25% lispro with 75% NPH
4 (5.7)
Premixed 30% aspart with 70% NPH before
breakfast ? degludec at bedtime
2 (2.8)
Premixed insulin BID
30% regular with 70% NPH
4 (5.7)
Lispro before breakfast ? glargine at bedtime 2 (2.8)
Premixed insulin 30% aspart with 70% NPH
before breakfast ? glargine at bedtime
8 (11.4)
Aspart before breakfast ? aspart before
lunch ? premixed insulin 30% aspart with
70% NPH before dinner
7 (10)
Regular insulin before breakfast ? regular
insulin before lunch ? premixed insulin 30%
regular with 70% NPH before dinner
2 (2.8)
Basal bolus
Glargine at bedtime with aspart thrice a day
before meals
6 (8.5)
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patient. No other side effects were reported,
including ketonuria.
DISCUSSION
In this retrospective study the addition of
dapagliflozin 10 mg resulted in a significant
improvement in glycaemic control and body
weight and a reduction in the dose, frequency
and cost of insulin therapy. Dapagliflozin, an
SGLT2 inhibitor, reduces HbA1c levels and
provides extra benefits beyond glycaemic
control. Although the efficacy of dapagliflozin
is evident from randomised control trials, its
performance outside a controlled environment
may be variable. The safety profile and cost also
present challenges to the use of medications in
real-world scenarios [11, 15–20, 28–31]. The
results of this study provide valuable evidence
on the clinical effectiveness, safety and
implications for the cost of treatment.
There was a 19.87% reduction in the total
daily dose of insulin from baseline in this study.
Wilding et al. evaluated the effect of adding
dapagliflozin to insulin in T2DM patients. The
study showed that the dose of insulin
progressively increased by ?18.3 IU/day over a
Table 3 Changes in study outcomes from baseline to 3-month follow-up period
Parameter Baseline 3-month follow-up after
addition of dapagliﬂozin
HbA1c %* 10.3 ± 2 8.2 ± 1
Weight in kg* 75.3 ± 13 72.9 ± 12
Insulin cost INR ($)* 79.5 ± 53 (1.19 ± 0.79) 61.7 ± 38 (0.92 ± 0.57)
Insulin dose units* 47.8 ± 30 38.3 ± 24
Cost of insulin in those spending
[100 INR/day ([$1.49/day)*
151.8 ± 33 (2.26 ± 0.49) 106.8 ± 29 (1.59 ± 0.43)
Number of insulin shots per day*
Four 5 (7.1) 4 (5.7)
Three 9 (12.8) 8 (11.4)
Two 30 (42.8) 26 (37.1)
One 26 (37.1) 28 (40)
Zero 0 4 (5.7)
Data are presented as mean ± SD for continuous variables and as n (%) for categorical variables. Paired t test was used to
calculate p values for continuous variables and Wilcoxon signed rank test for ordinal variables
* p\0.01 at 5% level of signiﬁcance
Fig. 2 Correlation between cost reduction and reduction
in total daily dose of insulin
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period of 104 weeks in patients who were
receiving placebo along with insulin; however,
the dose of insulin requirement remained
stable over the 104-week study period in
patients receiving dapagliflozin along with
insulin [33].
The cost of diabetes therapy in India is borne
by the patients and not by the health care
system [34]. Efficacy, effectiveness and safety
are insufficient if the therapeutic option is
financially not viable. Our study has shown an
overall reduction in insulin cost by 17.8 ± 15
INR per day ($0.27 ± 0.22 per day) in patients at
the end of the 3-month follow-up period. The
maximum benefit was seen in individuals
spending more than 100 INR per day ($1.49
per day) on insulin, the savings offsetting the
cost of dapagliflozin, which costs approximately
43 INR ($0.64) per dose. Similar results were
observed in another study wherein addition of
dapagliflozin to insulin was found to be a
cost-effective treatment option for T2DM
patients [27, 32].
Improved glycaemic control also warranted a
change in the insulin regimen and reduction in
the frequency of insulin administration in 15%
of the patients in this study. Such changes can
directly impact the health economics by
reducing the cost of medication and
monitoring. Decreased frequency of dosing
reduces pain and is also a fundamental
determinant of patient compliance and
preference [35]. Intangible psychological
benefits increase the productivity and quality
of life (QoL) [36]. Previous studies have reported
a decrease in the total daily dose of insulin with
the use of SGLT2 inhibitors with no difference
in the number of insulin shots per day [37–40].
Insulin use complicates diabetes care and
adds to weight gain and fear of injectables, thus
reducing adherence to treatment. Many studies
have demonstrated improved glycaemic control
and weight loss and a slight increase in
hypoglycaemia when patients were treated on
SGLT2 inhibitors and insulin
[6, 7, 33, 38, 39, 41]. Although the present
study did not evaluate the frequency of
hypoglycaemic episodes experienced by the
patients, none of them were observed to
experience severe hypoglycaemia during the
entire study period. Although the evidence
evaluating the overall efficacy and safety of
dapagliflozin as an add-on therapy to high-dose
insulin in T2DM patients is limited, most of the
available studies suggest that addition of
dapagliflozin reduces the HbA1c levels without
increasing the risk of hypoglycaemic events. In
addition, a small proportion of patients
reported genital mycotic infections during the
study period. It is important to mention that
such patients were successfully treated with
topical anti-fungal agents, which was a
one-time cost and did not exceed 43 INR
($0.64) per patient. Patients with T2DM often
experience genital infections caused by several
factors such as glucosuria, adherence of bacteria
to the uroepithelium and immune dysfunction.
Patients taking SGLT2 inhibitors viz.
dapagliflozin are more prone to genital
infections because these agents are known to
induce glucosuria pharmacologically. However,
these genital infections are generally not serious
and easily managed with anti-fungal agents
[42].
Some of the limitations of the study are the
short duration and small sample size. The
impact on the glycaemic variability, number
of hypoglycaemic episodes and cost of treating
hypoglycaemia was not analysed. Additionally,
it is important to mention that glycaemic
variability was not measured in this study as it
was a real-world retrospective study and
assessment of this parameter with a
continuous glucose monitoring device was not
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a part of routine care, so these data were not
available. The impact on the monitoring
frequency and SMBG costs were not analysed
as most patients were unable to produce records
of the same.
While it is easier to estimate the direct
reduction in daily health care-related costs,
the indirect health economic benefits of
improved glycaemic control, weight loss and
cardiovascular risk reduction are invaluable and
difficult to quantify monetarily. Direct costs
such as the cost of medication, investigations
and hospitalisation are easy to quantify, but the
indirect economic burden, such as absenteeism
from work, low self-esteem, depression and
caregiver burden, are difficult to assess and
were not assessed in this study.
Improved glycaemic control and weight
reduction are accompanied by a better QoL.
Long-term studies must be carried out to
evaluate the effect of this therapy on
long-term cardiovascular, micro- and
macrovascular complications in patients with
T2DM. The lack of integration among the
health care system, insurance providers and
the health care regulators and out of pocket
expenses for diabetes care have resulted in a
scarcity of information on pricing and cost
analysis studies on a national level. The results
of this study should be a premise for further
larger studies evaluating the cost of treatment
with a better integrated health care system to
ensure adequate cost management in the future
in a country like India. If the above findings can
be replicated in larger long-term studies, SGLT2
inhibitors may have the potential to occupy a
higher place in the treatment algorithm for
T2DM for health care providers, policy makers
and health insurers. A greater understanding of
health economic benefits is necessary,
especially in developing countries like India,
to ensure that the medications we prescribe are
indeed ‘value for money’.
CONCLUSION
The present study has demonstrated that the
addition of dapagliflozin to existing insulin and
OADs in uncontrolled T2DM patients reduces
HbA1C and weight, along with reducing the
insulin dose, frequency and cost.
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